Immunome (IMNM) to Release Earnings on Monday

Key Points

• Immunome will report Q1 2026 results before the market opens on Monday, May 11, with analysts forecasting a loss of ($0.60) EPS and revenue of $0.222 million; the company’s earnings call is scheduled for May 15 at 4:00 PM ET.
• Shares recently traded up 3.7% to $23.58, giving Immunome a market cap of about $2.67 billion; the stock has a negative P/E and a one-year range of $7.15–$27.65.
• Insiders sold 139,438 shares (~$2.96 million) in the past three months while institutional ownership stands at 44.58%; Wall Street’s consensus rating is a Moderate Buy with an average price target of $33.45.

Immunome (NASDAQ:IMNM - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $0.2220 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, analysts expect Immunome to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunome Trading Up 3.7%

NASDAQ:IMNM traded up $0.85 during mid-day trading on Monday, hitting $23.58. The company had a trading volume of 130,979 shares, compared to its average volume of 1,411,672. Immunome has a 1 year low of $7.15 and a 1 year high of $27.65. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -9.77 and a beta of 2.11. The business has a fifty day simple moving average of $21.88 and a 200-day simple moving average of $20.82.

Insider Buying and Selling

In related news, insider Jack Higgins sold 9,438 shares of the company's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the transaction, the insider directly owned 22,000 shares in the company, valued at $476,080. This represents a 30.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the company's stock in a transaction on Friday, March 20th. The stock was sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director owned 369,347 shares of the company's stock, valued at approximately $7,560,533.09. The trade was a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 139,438 shares of company stock worth $2,964,664 in the last three months. 7.21% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after buying an additional 2,909 shares during the period. Tower Research Capital LLC TRC lifted its position in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares during the period. Russell Investments Group Ltd. acquired a new stake in Immunome in the third quarter worth approximately $76,000. Velan Capital Investment Management LP acquired a new stake in Immunome in the third quarter worth approximately $117,000. Finally, Quarry LP acquired a new stake in shares of Immunome in the third quarter valued at $117,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IMNM. Stephens dropped their target price on Immunome from $33.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 4th. HC Wainwright began coverage on Immunome in a research report on Thursday, February 12th. They set a "buy" rating and a $40.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. Wall Street Zen lowered Immunome from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Finally, Craig Hallum boosted their price objective on Immunome from $33.00 to $36.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $33.45.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.